Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial.

ABSTRACT:

Background

Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for patients with CRPC remains unclear.

Objective

To evaluate whether ENZ or ABI is better as first-line treatment for CRPC.

Design setting and participants

An investigator-initiated, multicenter, randomized controlled trial was conducted in Japan. The study enrolled 203 patients with CRPC before chemotherapy between February 20, 2015, and July 31, 2019. Patients were randomly assigned 1:1 to the ENZ or ABI arm.

Outcome measurements and statistical analysis

The primary endpoint was time to prostate-specific antigen (PSA) progression. Secondary endpoints included the PSA response rate (≥50% decline

SUBMITTER: Izumi K 

PROVIDER: S-EPMC9257638 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature